Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.

Febrile neutropenia (FN) is a potentially fatal complication of chemotherapy. This prospective, observational study describes physicians' approaches toward assessing FN risk in patients receiving chemotherapy regimens with an intermediate (10-20 %) FN risk. In the baseline investigator asse...

ver descrição completa

Detalhes bibliográficos
Autores: Freyer, Gilles, Kalinka-Warzocha, Ewa, Syrigos, Konstantinos, Marinca, Mihai, Tonini, Giuseppe, Ng, Say Liang, Wong, Zee Wan, Salar, Antonio, Steger, Guenther, Abdelsalam, Mahmoud, DeCosta, Lucy, Szabo, Zsolt
Tipo de documento: artigo
Estado:Versión aceptada para publicación
Data de publicação:2015
País:España
Recursos:Universitat Pompeu Fabra
Repositório:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/25031
Acesso em linha:http://hdl.handle.net/10230/25031
http://dx.doi.org/10.1007/s12032-015-0682-z
Access Level:Acceso aberto
Palavra-chave:Quimioteràpia
Neutropènia
id ES_eca37d4582e7620366cfa1326cedb0a7
oai_identifier_str oai:repositori.upf.edu:10230/25031
network_acronym_str ES
network_name_str España
repository_id_str
spelling Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.Freyer, GillesKalinka-Warzocha, EwaSyrigos, KonstantinosMarinca, MihaiTonini, GiuseppeNg, Say LiangWong, Zee WanSalar, AntonioSteger, GuentherAbdelsalam, MahmoudDeCosta, LucySzabo, ZsoltQuimioteràpiaNeutropèniaFebrile neutropenia (FN) is a potentially fatal complication of chemotherapy. This prospective, observational study describes physicians' approaches toward assessing FN risk in patients receiving chemotherapy regimens with an intermediate (10-20 %) FN risk. In the baseline investigator assessment, physicians selected factors considered important when assessing overall FN risk and deciding on granulocyte colony-stimulating factor (G-CSF) primary prophylaxis (PP). Physicians then completed patient assessments using the same lists of factors. The final FN risk scores and whether G-CSF PP was planned were reported. The final analysis included 165 physicians and 944 patients. The most frequently considered factor in both assessments was chemotherapy agents in the backbone (88 % of investigator and 93 % of patient assessments). History of FN (83 %), baseline laboratory values (76 %) and age (73 %) were commonly selected at baseline, whereas tumor type (72 %), guidelines (62 %) and tumor stage (43 %) were selected most during patient assessments. Median investigator-reported FN risk threshold for G-CSF PP was 20 % (range 10-85 %). G-CSF PP was planned in 82 % of patients with an FN risk at or above this threshold; therefore, almost one-fifth of qualifying patients would not receive G-CSF PP. Physicians generally follow guidelines, but also consider individual patient characteristics when assessing FN risk and deciding on G-CSF PP. A standardized FN risk assessment may optimize the use of G-CSF PP, which may minimize the incidence of FN in patients undergoing chemotherapy with an intermediate FN risk. ClinicalTrials.gov Identifier: NCT01813721.Funding for this support was provided by Amgen (Europe) GmbH.Springer201520162015info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/25031http://dx.doi.org/10.1007/s12032-015-0682-zreponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraCatalánMedical Oncology. 2015 Oct;32(10):236c) Springer ( The original publication is available at www.springerlink.com)info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/250312026-06-12T07:21:37Z
dc.title.none.fl_str_mv Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
title Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
spellingShingle Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
Freyer, Gilles
Quimioteràpia
Neutropènia
title_short Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
title_full Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
title_fullStr Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
title_full_unstemmed Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
title_sort Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
dc.creator.none.fl_str_mv Freyer, Gilles
Kalinka-Warzocha, Ewa
Syrigos, Konstantinos
Marinca, Mihai
Tonini, Giuseppe
Ng, Say Liang
Wong, Zee Wan
Salar, Antonio
Steger, Guenther
Abdelsalam, Mahmoud
DeCosta, Lucy
Szabo, Zsolt
author Freyer, Gilles
author_facet Freyer, Gilles
Kalinka-Warzocha, Ewa
Syrigos, Konstantinos
Marinca, Mihai
Tonini, Giuseppe
Ng, Say Liang
Wong, Zee Wan
Salar, Antonio
Steger, Guenther
Abdelsalam, Mahmoud
DeCosta, Lucy
Szabo, Zsolt
author_role author
author2 Kalinka-Warzocha, Ewa
Syrigos, Konstantinos
Marinca, Mihai
Tonini, Giuseppe
Ng, Say Liang
Wong, Zee Wan
Salar, Antonio
Steger, Guenther
Abdelsalam, Mahmoud
DeCosta, Lucy
Szabo, Zsolt
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Quimioteràpia
Neutropènia
topic Quimioteràpia
Neutropènia
description Febrile neutropenia (FN) is a potentially fatal complication of chemotherapy. This prospective, observational study describes physicians' approaches toward assessing FN risk in patients receiving chemotherapy regimens with an intermediate (10-20 %) FN risk. In the baseline investigator assessment, physicians selected factors considered important when assessing overall FN risk and deciding on granulocyte colony-stimulating factor (G-CSF) primary prophylaxis (PP). Physicians then completed patient assessments using the same lists of factors. The final FN risk scores and whether G-CSF PP was planned were reported. The final analysis included 165 physicians and 944 patients. The most frequently considered factor in both assessments was chemotherapy agents in the backbone (88 % of investigator and 93 % of patient assessments). History of FN (83 %), baseline laboratory values (76 %) and age (73 %) were commonly selected at baseline, whereas tumor type (72 %), guidelines (62 %) and tumor stage (43 %) were selected most during patient assessments. Median investigator-reported FN risk threshold for G-CSF PP was 20 % (range 10-85 %). G-CSF PP was planned in 82 % of patients with an FN risk at or above this threshold; therefore, almost one-fifth of qualifying patients would not receive G-CSF PP. Physicians generally follow guidelines, but also consider individual patient characteristics when assessing FN risk and deciding on G-CSF PP. A standardized FN risk assessment may optimize the use of G-CSF PP, which may minimize the incidence of FN in patients undergoing chemotherapy with an intermediate FN risk. ClinicalTrials.gov Identifier: NCT01813721.
publishDate 2015
dc.date.none.fl_str_mv 2015
2015
2016
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/25031
http://dx.doi.org/10.1007/s12032-015-0682-z
url http://hdl.handle.net/10230/25031
http://dx.doi.org/10.1007/s12032-015-0682-z
dc.language.none.fl_str_mv Catalán
language_invalid_str_mv Catalán
dc.relation.none.fl_str_mv Medical Oncology. 2015 Oct;32(10):236
dc.rights.none.fl_str_mv c) Springer ( The original publication is available at www.springerlink.com)
info:eu-repo/semantics/openAccess
rights_invalid_str_mv c) Springer ( The original publication is available at www.springerlink.com)
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423356814557184
score 15,812429

Registros relacionados